Triage of high-risk patients – Update 2025

In the recent past, the nephroprotective treatment armamentarium has been significantly expanded. It is essential that impaired renal function is detected in good time in order for patients to receive these innovative treatment options, which act as an add-on to RAAS inhibition and additionally inhibit progression, within a reasonable period of time. SGLT-2-i as well as GLP-1-RA and non-steroidal MRA have now found their way into international guidelines due to their evidence-based favorable effects on the heart and kidneys.